November 2024 in “Journal of the European Academy of Dermatology and Venereology” This study found that nearly 40% of patients with severe alopecia areata who showed eyebrow or eyelash regrowth on baricitinib 4 mg achieved significant scalp hair regrowth by the second year of treatment.
29 citations
,
December 2022 in “Dermatology and Therapy” This study reported that patients with alopecia areata experienced significant increases in work productivity loss and activity impairment due to worsening emotional symptoms, highlighting a need for better treatments.
38 citations
,
March 2021 in “JAMA Dermatology” This cross-sectional survey study found that stigmatizing attitudes toward people with alopecia are present in various social and professional settings, with stigma levels varying by alopecia severity and perceptions of its medical nature.
3 citations
,
June 2023 in “Journal of dermatological treatment” This study found that patients with severe alopecia areata who experienced meaningful scalp hair regrowth showed greater improvements in health-related quality of life and reduced anxiety and depression compared to those with no or minimal regrowth.
August 2025 in “Dermatology and Therapy” This review reports that three JAK inhibitors—baricitinib, ritlecitinib, and deuruxolitinib—have gained FDA approval for treating alopecia areata due to their demonstrated efficacy in fostering hair regrowth in clinical trials.
